Peer-to-Peer Reviews: When Your Doctor Argues Your Case to the Insurer

The Most Powerful Step in the Appeal Process

A peer-to-peer review is a phone conversation between your prescribing doctor and a physician employed by (or contracted with) your insurance company. It happens after a prior authorization is denied and before you escalate to a formal written appeal or external review.

It's the single most effective step in the GLP-1 approval process because it puts your doctor — a clinician who has examined you — in direct conversation with another physician. The insurer's medical director can ask clarifying questions, and your doctor can provide context that doesn't fit neatly into a prior authorization form.

The success rate for peer-to-peer reviews on GLP-1 prior authorizations is significantly higher than for written-only appeals. When a prescriber can explain the full clinical picture — why this patient needs this medication at this time — approvals happen that wouldn't have happened on paper alone.

What Happens During the Call

The call typically lasts 10-20 minutes and follows a predictable structure:

Opening: The insurer's medical director identifies the case and states the reason for the denial.

Clinical presentation: Your prescriber presents your case — BMI history, comorbidities, prior treatment attempts, current lab values, and the clinical rationale for GLP-1 therapy.

Questions: The medical director asks clarifying questions. Common questions include: Has the patient tried behavioral modification? What was the outcome of prior pharmacotherapy? Are there contraindications to step therapy medications? What's the planned titration schedule and monitoring protocol?

Decision: The medical director may approve on the call, request additional documentation, or uphold the denial with a specific explanation. Some reversals happen in real-time during the call.

Your doctor's goal is straightforward: demonstrate that your case meets the insurer's clinical policy criteria and that GLP-1 treatment is medically necessary — not elective, not cosmetic, but clinically appropriate based on your health profile.

How to Prepare Your Prescriber

Your doctor wants to help, but they may not be familiar with the specific insurer's criteria or the most effective arguments for GLP-1 approval. Here's how you can prepare them:

Provide the denial letter. Make sure your prescriber has the exact denial reason, the insurer's clinical policy number (usually referenced in the letter), and the deadline for the peer-to-peer request.

Compile your documentation. Organize your lab results, BMI trend data, prior treatment records, and comorbidity diagnoses into a clear timeline. Your prescriber needs this information readily accessible during the call.

Share the insurer's clinical policy. Call your insurer and request their clinical policy for anti-obesity medications. This document lists the exact criteria they use to approve or deny coverage. Give this to your prescriber so they can frame their argument around the insurer's own requirements.

Discuss timing. Peer-to-peer calls often need to be scheduled within a narrow window (7-14 days after the denial). Make sure your prescriber's office knows the deadline and has the call request submitted promptly.

If the Peer-to-Peer Doesn't Work

Not every peer-to-peer results in approval. If the denial is upheld, your options are:

Formal written appeal: Incorporate the feedback from the peer-to-peer call. If the medical director cited a specific gap in your documentation, fill that gap and resubmit.

External review: Request an independent review by a third-party organization. This is your right under the ACA for fully-insured plans, and many self-insured employer plans offer it voluntarily. External reviewers are independent physicians who evaluate your case without a financial stake in the outcome.

Medication switch: If one GLP-1 is denied, ask whether a different formulation or brand is on formulary. Zepbound and Wegovy have different formulary placements on many plans.

Cash-pay pathway: Start treatment through a cash-pay telehealth provider while continuing the insurance appeal. If the appeal eventually succeeds, you can transition to the insured pathway.